MyAlcon Professionals Logo
MyAlcon for Consumer

My Alcon | Language

This page is available in English. Select below for other countries.

Select another country

Safety & dosing considerations for ROCKLATAN®

 (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Setting patient expectations about hyperemia

 

 

What to know about hyperemia

 

  • ROCK inhibitors may cause vasodilation on the ocular surface1
  • 59% of patients experienced hyperemia in clinical studies; however, only 5% of patients discontinued for this reason2       
     

 

What patients should know about hyperemia

 

  • ROCKLATAN® causes blood vessels in the eye to dilate, which may result in visible redness1 
  • Redness alone does not necessarily indicate an allergic reaction. Instruct patients to inform you if they develop inflammation or irritation of the eye or eyelids

 

Most occurrences of hyperemia were rated by investigators as mild to moderate.3

Conjunctival hyperemia severity with ROCKLATAN graphic

Discontinuation rate due to hyperemia: 5%2

 

See Important Safety Information about ROCKLATAN® on this page.

Help your patients get the most out of their ROCKLATAN® treatment with the MyAlcon Together Patient Support program

 

LEARN MORE ABOUT THE PROGRAM

Help your patients get the most out of their ROCKLATAN® treatment with the MyAlcon Together Patient Support program

 

LEARN MORE ABOUT THE PROGRAM

ROCKLATAN® should be taken once daily in the evening2

  • The recommended dose for ROCKLATAN® is one drop in the affected eye(s) once daily in the evening2
  • If you miss a dose of ROCKLATAN®, you should continue with your next dose the following evening2
  • If more than 1 eye drop is being used, the drugs should be administered at least 5 minutes apart2
  • Contact lenses should be removed prior to the administration of ROCKLATAN® and may be reinserted 15 minutes after administration2
  • Protect ROCKLATAN® from light. Until opened, store ROCKLATAN® at 36 °F to 46 °F. After opening, the product may be kept at 36 °F to 77 °F for up to 6 weeks. If after opening the product is kept refrigerated at 36 °F to 46 °F, then the product can be used until the expiration date stamped on the bottle
A person putting ROCKLATAN drops in their eye

ROCK=Rho kinase.


 

REFERENCES  
 

1. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.

2. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information. Aerie Pharmaceuticals, Inc., Irvine, CA. 2020.

3. Alcon data on file, 2017.

 

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
  • Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
  • Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
  • Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.
  • Remove contact lenses prior to administration and reinsert 15 minutes after administration.

 

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

 

Adverse Reactions

 

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

 

DOSAGE AND ADMINISTRATION

 

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

 

Please click here for full prescribing information for ROCKLATAN® Solution.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. 

©2023 Alcon Inc. 8/23 US-ROC-2300052